Cihan Ay and Colleagues on Large Language Models VS Thrombosis Experts
International Society on Thrombosis and Haemostasis (ISTH) shared on LinkedIn:
”AI meets thrombosis expertise
A new international study led in part by Cihan Ay, ISTH member and researcher at Medical University of Vienna, reveals that artificial intelligence (AI) language models can sometimes provide better answers than experts when educating patients about venous thromboembolism (VTE).
In complex clinical decision-making, the study found that AI recommendations were often on par with thrombosis specialists, a promising insight into the future of medical education and support tools.
Published in the Journal of Thrombosis and Haemostasis (JTH), the leading journal of the ISTH.
Learn more here.
Read the article here.”
Read the full article in JTH.
Article: Large language models versus thrombosis experts: A comparative study on patient education and clinical decision-making in venous thromboembolism
Authors: Nikola Vladic, Stephan Nopp, Ingrid Pabinger, Walter Ageno, Jean M. Connors, Sabine Eichinger, Cihan Ay, on behalf of the ClotGPT study group
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention